The Pharma Letter Pharmaletter News Articles
BRIEF—New national plasma agreement ensures supply for Australian patients
The Australian government has guaranteed the provision of a safe, secure and affordable supply of plasma…
Pharma boss speaks of hurt at ‘how badly this industry is talked about’
A survey compiled by US consulting firm the Reputation Institute put Bayer in the top 10 of a list of…
ASH presentation shows earlier treatment boosts efficacy of Imbruvica
In an oral presentation at the ongoing American Society of Hematology (ASH) meeting, Johnson & Johnson’s…
Newron making significant progress including US approval of Xadago
Italian CNS-focused drug developer Newron Pharmaceuticals today provided an end of year market update.
BRIEF—Janssen to drop rights to simeprevir effective June 2018
Swedish drugmaker Medivir says that Janssen Pharmaceuticals, a unit of US healthcare giant Johnson &…
Currently 940 clinical stage immuno-oncology agents being developed, report
The USA-based Cancer Research Institute (CRI) last week published a report that provides a first-of-its-kind…
Look back at pharma news to Dec 8
Among last week’s most interesting news were two acquisition deals in the field of immuno-oncology:…
UK pharma and biotech welcome Brexit breakthrough, but with caveats
The news early Friday morning that Britain and the European Union had finally agreed that enough progress…
SAGE-217 succeeds in major depressive disorder trial
Shares of CNS drug developer Sage Therapeutics surged yesterday, after the company revealed a second…
J&J and Sanofi lead ranking of clinical trial transparency
Pharmaceuticals and healthcare industry monitor Bioethics International has published its Good Pharma…
UK reverses reimbursement decision on Eisai's kidney cancer therapy
In a reversal of its earlier draft decision, the UK’s health technology assessor has provided final…
BRIEF—Generex out-licenses prostate cancer vaccine AE37 in China
Canada-headquartered Generex Biotechnology Corporation (OTCQB:GNBT) yesterday announced that its wholly-owned…
Kite gets wind in its sails as Gilead boosts cell therapy investment
Three months after Gilead Sciences bought fellow Californian biotech Kite Pharma, the HCV specialist…
ThromboGenics struggles to find patients for eye disease study
Belgian biotech ThromboGenics is scrapping its Phase II CIRCLE study of THR-409 (ocriplasmin), as not…
India’s commitment to ‘Ending the AIDS’ epidemic
The occasion of World AIDS Day was as good as any for India to launch a National Strategic Plan 2017-24,…
US neurologists’ increased focus on Ocrevus positioning in relapsing forms of MS
Seven months post-launch, the clear majority of US neurologists (n=103) have initiated at least one patient…
BRIEF—EFPIA response to EXPH draft opinion on payment for high-cost novel meds
The European Federation of Pharmaceutical Industries and Associations (EFPIA) believes that the recently…
BRIEF—Alexion inks deal to explore new drug delivery formulations
Nasdaq-listed Alexion Pharmaceuticals and Halozyme Therapeutics have agreed a deal based on the latter…
Medicines access group takes aim at Sovaldi patents
Two new patent challenges have been launched by the New York-based patient access and public health activist…
Patient advocacy group warns of steep price rises for certain medicines
A report from advocacy group AARP - the American Association of Retired Persons - has found that retail…
BRIEF—Australia approves Mavenclad for relapsing-remitting multiple sclerosis
Germany’s Merck KGaA has received approval from Australia’s medicines regulator for Mavenclad for…
Juno Therapeutics signs a trio of licensing deals
USA-based Juno Therapeutics rose 4% in pre-market trading, after it announced three license agreements…
Transgene and BioInvent agree viral-based immuno-oncology collaboration
Immuno-oncology specialist BioInvent International and viral-based immunotherapy company Transgene have…
bluebird bio partners with Scottish firm on CAR-T cell therapies
bluebird bio has signed a strategic R&D collaboration with Scottish immunotherapy company TC BioPharm…
Astellas inks partnership on rice-based oral vaccine
Japanese drug major Astellas Pharma is partnering with academia to develop rice-based vaccines, which…
Unlocking the potential of SMEs is key to combating AMR
Last week, the UK government published its latest annual update on its five year strategy to combat antimicrobial…
BRIEF—New positive data for Kisqali combination in advanced breast cancer
Novartis has announced positive results from the MONALEESA-7 trial investigating a Kisqali (ribociclib)…
GSK and Novartis being sued for alleged misleading representations in Australia
The Australian Competition and Consumer Commission (ACCC) has instituted proceedings in the Federal Court…
NICE draft guidance on ceritinib and glecaprevir with pibrentasvir
The UK’s National Institute for Health and Care Excellence (NICE) has today published draft guidance…
New report explores what’s in store for Pharma and Biotech in 2018
The upward momentum seen in the pharma and biotech sectors during 2017 looks set to continue into 2018,…
Feed Fetched by RSS Dog.